Biomaterial strategies for improved intra‐articular drug delivery
Abstract
Osteoarthritis (OA) is a joint degenerative disease that has become one of the leading causes of disability in the world. It is estimated that OA affects 50 million adults in the United States. Currently, there are no FDA‐approved treatments that slow OA progression and its treatment is limited to pain management strategies and life style changes. Despite the discovery of several disease‐modifying OA drugs (DMOADs) and promising results in preclinical studies, their clinical translation has been significantly limited because of poor intra‐articular (IA) bioavailability and challenges in delivering these compounds to tissues of interest within the joint. Here, we review current OA treatments and their effectiveness at reducing joint pain, as well as novel targets for OA treatment and the challenges related to their clinical translation. Moreover, we discuss intra‐articular (IA) drug delivery as a promising route of administration, describe its inherent challenges, and review recent advances in biomaterial‐based IA drug delivery for OA treatment. Finally, we highlight the potential of tissue targeting in the development of effective IA drug delivery systems.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Aug 24, 2020
- Source ID
- 10.1002/jbm.a.37074
Entities
People
- Andrés J García
- Lina María Mancipe Castro
- Robert E Guldberg
Organizations
- Georgia Tech
- National Institute of Arthritis and Musculoskeletal and Skin Diseases
- United States Department of Defense
- University of Oregon